Cladribine, Cytarabine and Venetoclax for HR-MDS
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 60 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Tags
- Antimetabolites, BCL-2 Inhibitor, Chemotherapy, Hypomethylating Agents (HMA)
- Trial Type
- Treatment
- Last Update
- 2 days ago
- SparkCures ID
- 1495
- NCT Identifier
- NCT05365035
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.